The decision
Not another data deck. The science is built around a human thread, so that out of fifty pitches, this is the one an investor brings up in the meeting afterward.
The brief
A 15-minute investor pitch for a two-day conference in New York, in front of around 150 pharma investors. They came with a data-heavy deck they'd already refined, and wanted our input on the pitch itself, not just the design.
What I saw
Fifty startups present across two days, on a program that also includes Nobel laureates and professors. The pitch doesn't close a round on stage. Its job is to earn the meetings that happen after, so the only thing that matters is being the one people bring up later.
The room is senior and knows the field. Explaining the market or the stages of drug development would burn the little attention there is. What they wouldn't get anywhere else is a reason to remember this one.
How it works
Start with why, without sounding like everyone else
The CMO asked to open on the why, and the why is where the pitch is either won or lost. The catch in pharma is that "why" almost always lands generic, every company is curing a disease. The work was making this one specific enough that it couldn't be swapped into another company's deck.
The founder's 25 years
In a working session the CMO mentioned in passing that the founder had spent 25 years on this compound, her life's work. We stopped there and made it the opening. Investors remember people, not compounds. Twenty-five years on one molecule is also a signal in itself, nobody arrives at that by accident.
One line, start and end
A single claim the audience should walk out with, planted early and called back at the close.
What we left out
No lecturing on the market or the stages of drug development. This room already knows them. Cutting that made room for what they'd remember.
One idea per slide
We split the overloaded slides apart, so each one carries a single point instead of a wall of data.
Status
The pitch is set for a conference this September.